US Pharma MarketingThe post Novocure’s Optune Gio fails to show benefit at earlier stage appeared first on Clinical Trials Arena.
Novocure’s Optune Gio fails to show benefit at earlier stage
The Phase III TRIDENT study failed to show statistical significance in OS when Novocure's Optune Gio was used earlier. The Phase III TRIDENT study failed to show statistical significance in OS when Optune Gio was used earlier. NovoCure first gained US approval for its TTFields therapy in 2011. Credit: Pavlo Gonchar/SOPA Images/LightRocket via Getty Images Novocure’s stock has dropped more than 15% after its Phase III glioblastoma study of Optune Gio failed to show benefit when used at an earlier stage. The Phase III TRIDENT trial (NCT04471844) evaluated the initiation of Tumour Treating Fields (TTFields) therapy, Optune Gio, for newly…
The Phase III TRIDENT study failed to show statistical significance in OS when Novocure's Optune Gio was used earlier.
Source: Clinical Trials Arena